^
Association details:
| Biomarker: | KMT2A rearrangement |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug Class: | Menin-MLL inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Menin inhibitors as targeted therapeutics in KMT2a rearranged infant leukemia and the identification of effective treatment combinations.
Published date:
05/26/2022
Excerpt:
...we evaluated the effect of multiple menin inhibitors and effective drug combinations for the treatment of KMT2A-rearranged infant leukemia….Within the panel of menin inhibitors, infant B-ALL cells were found to be more sensitive to MI-463, MI-503 and MI-136 with a mean IC50 of 5.9µM, 6.1µM and 10.2µM, respectively....In this study, we present and discuss the initial proof-of-concept preclinical data for the effective anti-leukemic activity of menin inhibition against KMT2A-rearranged infant leukemia cells.
DOI:
10.1200/JCO.2022.40.16_suppl.10024
